MedTrace Logo

Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics

NCT02951702 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2017-12-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if oral vancomycin used as primary Clostridium difficile prophylaxis can reduce the incidence of this infection in high-risk patients.

Conditions

  • Clostridium Difficile Infection
  • Prophylaxis
  • Vancomycin

Interventions

DRUG

Vancomycin Oral

This arm will receive oral vancomycin 125 mg daily if "high risk" and determined to be appropriate by an ID physician

Sponsors & Collaborators

  • St. Luke's Hospital, Chesterfield, Missouri

    lead OTHER

Principal Investigators

  • Ryan E Medas, PharmD · St. Luke's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-05-31
Completion
2017-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02951702 on ClinicalTrials.gov